AOD-9604: The Complete Lipolytic Peptide Research Guide

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Written by Sophie Chen. Reviewed by Morgan Ellis, MSc Endocrinology · Last updated: 23 May 2026

AOD-9604 is one of the most-studied “failed” weight-loss drugs of the last twenty-five years — and one of the most-bought research peptides today. Originally developed by Metabolic Pharmaceuticals at Monash University in Melbourne under the name Anti-Obesity Drug 9604, this 16-amino-acid synthetic peptide carries the lipolytic tail of human growth hormone plus a single tyrosine residue at the N-terminus. It went the full distance through a Phase 2b human obesity trial, did not reach its primary weight-loss endpoint, and was discontinued as a drug candidate in 2007. What it left behind is one of the cleanest safety datasets in peptide research and a precise mechanistic tool for studying adipocyte lipolysis without raising IGF-1.

This guide explains what AOD-9604 actually is at the molecular level, why it didn’t beat placebo on weight loss but still passed safety review, how it differs from its sister molecule HGH Fragment 176-191, what dose ranges show up in the published literature, and what to look for on a Certificate of Analysis before committing to a protocol.

Important framing: Throughout this guide, “research” refers to bench, animal, or human-subject investigations conducted under appropriate ethical and regulatory oversight. AOD-9604 is offered as a research-grade laboratory reagent (CAS 221231-10-3; HPLC-verified purity; COA-keyed lots) — not as a personal-use therapeutic, weight-loss medication, or anti-obesity drug.

What Is AOD-9604?

AOD-9604 is a 16-amino-acid synthetic peptide whose sequence corresponds to residues 177-191 of the human growth hormone polypeptide chain, with an additional tyrosine residue at the N-terminus. Its molecular weight is approximately 1817 daltons. It was developed by Metabolic Pharmaceuticals as a candidate obesity drug and engages the same lipolytic mechanism as the unmodified HGH Fragment 176-191 — without binding the growth hormone receptor or raising IGF-1.

The drug’s history is unusually well-documented for a research peptide. In the late 1990s, the Monash University endocrinology group led by Frank Ng was dissecting the structure-function relationships within the 191-amino-acid HGH molecule. They identified that the lipolytic activity of full-length growth hormone could be reproduced by a small C-terminal fragment, with the growth-promoting, insulin-antagonist, and IGF-1-elevating activities all residing elsewhere in the molecule. Metabolic Pharmaceuticals — spun out of Monash — patented an N-terminal-tyrosine-modified version of that fragment as AOD-9604 and pushed it through formal drug development.

The compound progressed through Phase 1, Phase 2a (showing dose-dependent lipolysis in obese humans), and a Phase 2b multi-centre trial in 2007 with 536 subjects over 24 weeks. The primary efficacy endpoint — clinically meaningful weight loss versus placebo — was not met. The drug was discontinued as a candidate weight-loss therapeutic but remained available as a research compound, and Metabolic Pharmaceuticals subsequently pivoted to investigating AOD-9604’s role in cartilage repair and osteoarthritis — work that continued through the 2010s with mixed published results.

Why the Tyrosine?

The unmodified HGH Fragment 176-191 sequence has the residues Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe — a 15-amino-acid peptide. AOD-9604 adds a single tyrosine residue at the N-terminus, giving Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe — 16 amino acids total. The extra tyrosine was added during patent drafting to create a structurally distinct molecule (intellectual property protection) and was found to be pharmacokinetically advantageous (modestly improved metabolic stability). Pharmacologically the two molecules are very similar; legally and for citation purposes they are not interchangeable.

How Does AOD-9604 Work? (Mechanism)

The mechanism of AOD-9604 is genuinely different from full-length growth hormone, and understanding the distinction matters because researchers frequently misuse the molecule as a “weaker HGH”. It is not weaker HGH. It engages an entirely different receptor pathway.

The β3-adrenergic-like pathway

The canonical mechanistic study by Heffernan and colleagues (Endocrinology, 2001) demonstrated AOD-9604’s mode of action using β3-adrenergic receptor knockout mice. In wild-type animals, AOD-9604 administration increased fat oxidation and reduced body weight in standard obesity models. In β3-AR knockout mice, the effect was substantially attenuated — strongly suggesting that the peptide’s lipolytic action depends on the β3-adrenergic pathway expressed on adipocytes.

The β3-adrenergic receptor is enriched on white and (more importantly) brown adipose tissue, where its activation drives hormone-sensitive lipase upregulation, increases triglyceride breakdown into free fatty acids and glycerol, suppresses lipogenic enzymes such as acetyl-CoA carboxylase, and stimulates mitochondrial fatty-acid β-oxidation. AOD-9604 appears to amplify this signalling, though the exact receptor-binding details remain incompletely characterised.

What AOD-9604 does NOT do

The companion Heffernan paper (International Journal of Obesity, 2001) on chronic administration in obese mice showed an important negative result: serial serum IGF-1 measurements remained at baseline across 14-day administration, in sharp contrast to full-length recombinant HGH which produced expected dose-dependent IGF-1 rises in the same animal model. AOD-9604 also did not produce glucose intolerance, did not stimulate longitudinal bone growth in juvenile animals, and did not produce the joint pain or fluid retention characteristic of GH excess.

For researchers studying obesity, this matters. Conventional GH-related weight-loss research is confounded by IGF-1 elevation and its downstream proliferative signalling. AOD-9604 lets investigators isolate the lipolytic component of GH biology without those confounders — the entire reason Metabolic Pharmaceuticals built a drug-development programme around it.

Key Uses & Applications of AOD-9604

AOD-9604 has no formally approved therapeutic indication in any major jurisdiction. The Phase 2b weight-loss trial did not meet its primary endpoint, and the drug-development programme for anti-obesity use was discontinued. Subsequent investigation has focused on three research domains.

Adipose lipolysis research

The cleanest experimental application: studying free-fatty-acid mobilisation and oxidation kinetics in adipose tissue without confounding by IGF-1 or insulin antagonism. Rodent obesity models consistently show measurable reductions in visceral and subcutaneous fat mass over 4–8 week dosing windows when animals are on standardised diets.

Cartilage and osteoarthritis research

After the obesity programme was discontinued, Metabolic Pharmaceuticals pursued AOD-9604 in osteoarthritis based on emerging data that growth-hormone-derived peptides may have chondroprotective effects. Phase 2 clinical work was conducted but did not lead to a regulatory submission. The published cartilage-repair work is more limited than the obesity literature but represents a separate research thread.

Combination protocol research

Like its sister HGH Fragment 176-191, AOD-9604 is frequently paired in research stacks with compounds where IGF-1 elevation or pituitary suppression would confound the design. Common pairings:

• CJC-1295 + Ipamorelin stacks — peripheral lipolysis adjunct to systemic GH pulse
• GLP-1 agonist studies (Semaglutide, Tirzepatide, Retatrutide) — adipocyte-direct mechanism complementing central appetite suppression
• Mitochondrial fat-loss research (5-Amino-1MQ, MOTS-c) — different but compatible metabolic axes

For the broader fat-loss landscape, see our best peptides for fat loss hub.

AOD-9604 Safety Profile, Side Effects & Dosing

The AOD-9604 safety profile is genuinely unusual for a research peptide because it carries a full Phase 2b human safety dataset — 536 subjects over 24 weeks, with detailed adverse-event reporting. That makes the dose-response side-effect picture clearer than for almost any non-approved research peptide.

Documented side effects

Dose ranges in published literature

• Preclinical mouse/rat lipolysis research: 250–500 mcg/kg/day, typically delivered subcutaneously in 1–2 daily doses.
• Phase 2b human obesity trial: 1 mg/day subcutaneous for 24 weeks (this is the most-cited human dose).
• Common research protocols: 250–500 mcg twice daily, pre-fasted morning and pre-bed; total daily dose 500 mcg–1 mg.
• Cartilage-research protocols: Intra-articular and oral formulations were tested — oral bioavailability is poor but topical/local delivery showed measurable cartilage marker changes in some studies.

What Does the Research Say?

The AOD-9604 evidence base is unusually deep for a research peptide because Metabolic Pharmaceuticals pursued formal drug development. For broad context on the obesity epidemiology that drove the original development programme, see the WHO obesity and overweight fact sheet and the NIDDK adult overweight and obesity overview.

Qualifying language: The preclinical mechanism is well established — β3-adrenergic-dependent adipocyte lipolysis without IGF-1 elevation. Early human studies showed signal. The Phase 2b magnitude-of-effect data does not support the molecule as a stand-alone weight-loss therapeutic. The honest reading: real mechanism, real safety data, modest effect-size for weight loss in humans. For comparative context with current obesity pharmacotherapy, see also the NHS overweight and obesity overview.

AOD-9604 vs Alternatives — Comparison Table

How to decide

• Citing Metabolic Pharmaceuticals’ published clinical-trial data: AOD-9604 specifically. The unmodified HGH Fragment 176-191 cannot substitute.
• Pure mechanistic adipocyte lipolysis without IGF-1 confounder: Either AOD-9604 or HGH Fragment 176-191 — both work, both have the same mechanism.
• Magnitude weight-loss is the primary endpoint: GLP-1 agonists (Semaglutide, Tirzepatide) substantially outperform any GH-pathway peptide.
• Lean mass plus fat loss in the same protocol: Full HGH 191AA or a CJC-1295 + Ipamorelin pulse-stimulator approach.
• Combination protocols where IGF-1 elevation would confound: AOD-9604 stacks cleanly because it doesn’t engage the GH receptor or perturb pituitary feedback.

How to Use AOD-9604 — Practical Research Guidance

Reconstitution

AOD-9604 ships as lyophilised powder, typically 2–5 mg per vial. Reconstitution follows the standard small-peptide protocol:

1. Allow vial to reach room temperature before opening (avoid temperature shock).
2. Inject bacteriostatic water down the inside wall of the vial — not directly onto the cake — at a volume that gives a convenient working concentration. For a 5 mg vial, 2 mL BAC water yields 2.5 mg/mL (250 mcg per 0.1 mL on an insulin syringe).
3. Swirl gently for 30–60 seconds; do not shake or invert vigorously.

For the reconstitution math and concentration reference tables, see our generalised reconstitution math guide and the dedicated BAC water guide.

Storage and stability

• Lyophilised vial (unopened): 2–8 °C refrigerated; stability 24+ months. Long-term freezer storage at −20 °C extends shelf life; minimise freeze-thaw cycles.
• Reconstituted vial: 2–8 °C refrigerated; use within 28 days. AOD-9604’s small size and synthetic origin make it more stable in solution than full-length recombinant HGH.
• Light protection: Store in original carton or opaque box.
• Transport: Cold-chain preferred — see our peptide storage and cold-chain protocol.

Injection technique and timing

Subcutaneous injection is standard. 29G or 31G insulin syringes with ½-inch needles. Common research-protocol sites: abdominal wall (avoiding 2 cm around the umbilicus), lateral thigh, upper outer arm. Rotate sites to minimise local irritation. See peptide injection routes guide for SC/IM/intranasal trade-offs.

Timing protocols used in published research and biohacker self-reports:

• Twice-daily fasted-window: 250 mcg pre-breakfast (fasted) + 250 mcg pre-bed. Rationale: amplify endogenous lipolysis peaks during fasted morning and overnight windows.
• Single morning dose: 500 mcg pre-breakfast fasted. Adherence-friendly; misses the pre-bed window.
• Phase 2b protocol replication: 1 mg single daily dose. Matches the published human-trial schedule for citation continuity.

Browse our research-grade AOD-9604 product page for vial pricing, batch documentation, and lot traceability.

Evaluating an AOD-9604 Certificate of Analysis

AOD-9604 is produced by solid-phase peptide synthesis (Fmoc strategy). Synthesis byproducts — incomplete couplings, deletion sequences, racemized residues — accumulate without rigorous purification, and lot-to-lot variability is the single biggest threat to a clean research result. A legitimate batch-specific COA should document:

• Purity by RP-HPLC: ≥98% main peak. Below 96% rejects the lot.
• Identity by mass spectrometry: Observed molecular weight ≈1817 Da (the expected exact mass for the 16-amino-acid Tyr-hGH 177-191 sequence).
• Sequence verification: N-terminal sequencing or MS/MS confirming the Tyr-hGH 177-191 backbone.
• Bacterial endotoxin: <1 EU/mg (LAL test).
• Residual solvent: <0.5% TFA (typical purification system), <0.1% acetonitrile.
• Counter-ion content: Acetate or TFA salt form noted; net peptide content stated separately from total vial mass.
• Water content: <8% by Karl Fischer titration (lyophilised cake should be effectively dry).

A COA missing any of these rows is incomplete documentation, not a quality certificate.

Frequently Asked Questions

Is AOD-9604 the same as HGH Fragment 176-191?

Very close, but not identical. Both are 16-amino-acid synthetic peptides derived from the C-terminal lipolytic region of human growth hormone, and both engage the same proposed β3-adrenergic-like mechanism. AOD-9604 carries an additional N-terminal tyrosine residue (so its sequence is Tyr-hGH 177-191 versus HGH 176-191) — a difference added during patent drafting that confers modestly improved metabolic stability. For mechanistic research the two molecules can substitute; for citing Metabolic Pharmaceuticals’ published Phase 2b clinical-trial data the molecules are not interchangeable.

Why did AOD-9604 fail the obesity trial?

The Phase 2b trial (2007, 536 subjects, 24 weeks at doses up to 1 mg/day SC) showed only modest weight reduction — the mean weight loss versus placebo did not reach statistical significance at the primary endpoint. The mechanism worked as designed (lipolysis without IGF-1 elevation), but the magnitude of effect at tolerable doses was too small to support a regulatory submission for obesity. By 2007, GLP-1 receptor agonists were emerging as the much-stronger weight-loss drug class, and the gap between AOD-9604’s effect size and the emerging GLP-1 standard was too large to bridge.

Does AOD-9604 actually cause weight loss?

In rodent obesity models, yes — consistently and reproducibly. In humans, yes but modestly — early-phase trials showed measurable body-composition shifts toward reduced fat mass, but the Phase 2b magnitude (mean ~2 kg over 24 weeks) was not large enough to be clinically significant against placebo. For researchers expecting GLP-1-magnitude weight loss, AOD-9604 will disappoint. For researchers wanting clean mechanistic isolation of GH-derived lipolysis, it delivers what the literature describes.

Will AOD-9604 raise my IGF-1?

No. This is one of the molecule’s defining pharmacological features and has been confirmed across both preclinical animal models and 24-week Phase 2b human data — serial serum IGF-1 measurements remain at baseline through AOD-9604 administration, in clear contrast to full-length recombinant HGH 191AA which produces dose-dependent IGF-1 elevation. This separation is the entire reason the molecule exists as a research tool.

Can AOD-9604 be taken orally?

As an injectable research peptide, no — gastric proteases degrade the 16-amino-acid chain on oral ingestion, and bioavailability is poor. Metabolic Pharmaceuticals did investigate oral formulations during the cartilage-repair phase of development, with limited efficacy. For weight-loss-focused research, subcutaneous injection is the only viable administration route. Products marketed as “oral AOD-9604” or “sublingual AOD-9604” do not deliver bioavailable peptide.

Is AOD-9604 banned in sport?

Yes. The World Anti-Doping Agency (WADA) includes “growth hormone fragments” — including AOD-9604 — on the Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Detection methodology for AOD-9604 is well characterised in the anti-doping literature. Researchers working with athletes or in sports-related contexts must consider WADA implications before any human protocol.

Does AOD-9604 help with cartilage or osteoarthritis?

Metabolic Pharmaceuticals investigated AOD-9604 in osteoarthritis after the obesity programme was discontinued, with Phase 2 work conducted on intra-articular and oral formulations. Published data showed modest cartilage-marker changes but did not lead to a regulatory submission. The osteoarthritis evidence is much thinner than the obesity-research data, and the molecule should not be presented as an established cartilage therapy.

Can I stack AOD-9604 with GLP-1 agonists like Semaglutide?

In research protocols, yes — the two mechanisms are biologically compatible and address complementary pathways. AOD-9604 provides adipocyte-direct peripheral lipolysis via the β3-adrenergic-like mechanism; Semaglutide and Tirzepatide provide central appetite suppression and incretin-axis effects. There are no documented pharmacological interactions, and the side-effect profiles do not overlap meaningfully. As always, combination protocols in human subjects require appropriate ethical oversight.

The Bottom Line

AOD-9604 occupies a specific and well-documented niche in the research-peptide landscape: it is the patented N-terminal-tyrosine version of the C-terminal HGH lipolytic fragment, the most-clinically-tested member of the GH-fragment family, and the cleanest single dataset for studying β3-adrenergic-mediated adipose lipolysis in research subjects. The Phase 2b clinical trial established its safety in 536 subjects over 24 weeks but did not establish it as a magnitude-weight-loss drug versus placebo. The mechanism is real; the effect-size for weight loss is modest.

For researchers, the practical question is not “does AOD-9604 cause weight loss?” — it’s “does the experimental design need clean adipocyte-lipolysis isolation without IGF-1 confounders?” If the answer is yes, AOD-9604 is the most-documented tool available, with peer-reviewed mechanistic work, β3-AR knockout confirmation, and a clean 24-week human safety dataset. For researchers wanting magnitude weight-loss endpoints, GLP-1 receptor agonists are the appropriate compound class, not the GH fragments.

Explore our research-grade AOD-9604 with batch COA documentation, or compare against the unmodified HGH Fragment 176-191 when no clinical-citation requirement applies. For the broader fat-loss research landscape, see the best peptides for fat loss hub; for context on the GH cascade more generally, see our companion guides to recombinant HGH 191AA and the HGH Fragment 176-191 research guide. The full peptide catalogue covers complementary fat-loss compounds including 5-Amino-1MQ, Adipotide, and the GLP-1 agonists Semaglutide, Tirzepatide, and Retatrutide.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.